

**Jean-Bernard Deloye, Head of Market Access,  
becomes part of Leem's board,  
the French industry association for pharmaceutical companies**

**New York, N.Y (USA) and Paris (France), May 29, 2019 – Zionexa, a radiopharmaceutical company specialized in the development and commercialization of innovative molecular imaging companion diagnostics (CDx) for targeted therapies in oncology, today announced that Jean-Bernard Deloye, Head of Market Access, becomes part of Leem's board. Leem is the French industry association which represents drug companies operating in France.**

On May 28, 2019, Leem's board has co-opted five new members, including Jean-Bernard Deloye, Head of Market Access at Zionexa. He becomes part of the subgroup "small French laboratories" of the board. On a national level, Leem acts as a champion and advocate for the pharmaceutical industry. In this capacity, it participates in numerous official, ministerial and inter-ministerial committees. Leem is a member of the French Federation of Healthcare Industries (FEFIS) and of the French Enterprise Movement (MEDEF). At international level, Leem is a member of the European Federation of Pharmaceutical Associations and Industries (EFPIA) and of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

With more than 25 years of experience in pharmacy and especially in radiopharmacy, Jean-Bernard Deloye has held many management positions at Medgenix Diagnostic and MDS Nordion, before co-founding Cyclopharma, a radiopharmaceutical laboratory specialized in production and commercialization of molecular imaging solutions.

Since 2018, Jean-Bernard Deloye is General Manager and Head of Market Access at Zionexa, company specialized in development and commercialization of molecular imaging solutions for targeted therapies in oncology.

*« This new mission is a privilege. Leem's board ensures the profession representativeness and set strategic orientations, while promoting our sector, mostly in France but also internationally. » – Jean-Bernard Deloye, Head of Market Access.*

**About Zionexa – [www.zionexa.com](http://www.zionexa.com)**

Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, companion diagnostics (CDx) for targeted therapies in oncology, to improve patients' pathway and provide them a better quality of life.

**Zionexa Contacts**

Mathilde Bouscaillou  
Communication Manager  
[mathilde.bouscaillou@zionexa.com](mailto:mathilde.bouscaillou@zionexa.com)  
+33 6 47 00 82 71

**Press Contacts – NewCap Media**

Annie-Florence Loyer  
[afloyer@newcap.fr](mailto:afloyer@newcap.fr)  
+33 1 44 71 00 12  
+33 6 88 20 35 59

Léa Jacquin  
[ljacquin@newcap.fr](mailto:ljacquin@newcap.fr)  
+33 1 44 71 20 41  
+33 6 58 14 84 66